Intervention

Selinexor

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15
Recruiting2
Common conditions25
Lead sponsors shown11
Advertisement

Clinical trials

15 shown
Second-line Immunotherapy for ES-SCLCNCT06853678 · 2025-02-28
RECRUITING
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)NCT05035745 · 2021-03-01
RECRUITING
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNCT07172412 · 2025-11-01
NOT_YET_RECRUITING
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory DiseaseNCT04984330 · 2021-12-01
WITHDRAWN
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;NCT04534725 · 2020-12-17
COMPLETED
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)NCT03095612 · 2018-03-22
TERMINATED
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung CancerNCT02536495 · 2015-09-01
WITHDRAWN
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)NCT02402764 · 2015-07-08
COMPLETED
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26
TERMINATED
Selinexor in Treating Patients With Relapsed Small Cell Lung CancerNCT02351505 · 2015-05-01
TERMINATED
Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsNCT02367690 · 2015-01-01
WITHDRAWN
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate CancerNCT02215161 · 2014-09-02
TERMINATED
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic TumorsNCT02250885 · 2014-08-01
COMPLETED
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)NCT02146833 · 2014-05-01
TERMINATED
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor CancerNCT01607905 · 2012-06-18
COMPLETED

Common conditions

Advanced Malignant Solid Neoplasm1Advanced Refractory Solid Tumors1Advanced Triple Negative Breast Cancers1AL Amyloidosis1Amyloid1Amyloidosis1Breast Cancer1Cancer1Carcinoma, Neuroendocrine1Castration Levels of Testosterone1Clinical Stage III Cutaneous Melanoma AJCC v81Clinical Stage IV Cutaneous Melanoma AJCC v81Covid191Diabetic Foot Ulcers1Extensive Stage Lung Small Cell Cancer1Extensive Stage Small Cell Lung Cancer (ES-SCLC)1Fallopian Tube Carcinoma1Hormone-Resistant Prostate Cancer1Metastatic Lung Non-Small Cell Carcinoma1Metastatic Malignant Solid Neoplasm1Metastatic Melanoma1Metastatic Prostate Carcinoma in the Soft Tissue1Metastatic Renal Cell Carcinoma1Metastatic Triple Negative Breast Cancers1Non-small Cell Lung Cancer1

Trial status mix

TERMINATED5
COMPLETED4
WITHDRAWN3
RECRUITING2
NOT_YET_RECRUITING1

Phase mix

PHASE210
PHASE16
EARLY_PHASE11
NA1
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.